EricJWhitmanMD

PubMed

• Phase IIIb safety results from an expanded-access protocol of talimogene laherparepvec for patients with unresected, stage IIIB-IVM1c melanoma.
  Chesney, J.,Awasthi, S.,Curti, B.,Hutchins, L.,Linette, G.,Triozzi, P.,Tan, MCB.,Brown, R. E.,Nemunaitis, J.,Whitman, E.,Windham, C.,Lutzky, J.,Downey, G. F.,Batty, N....> ;Melanoma Res.. 2017 Nov 28
• Systemic versus local responses in melanoma patients treated with talimogene laherparepvec from a multi-institutional phase II study.
  Kaufman HL, Amatruda T, Reid T, Gonzalez R, Glaspy J, Whitman E, Harrington K, Nemunaitis J, Zloza A, Wolf M, Senzer NN> ;J Immunother Cancer. 2016-01-01
• 41 citations
  Evaluation of the ETS-Related Gene mRNA in Urine for the Detection of Prostate Cancer
  Kevin R. Rice, Yongmei Chen, Amina Ali, Eric J. Whitman, Amy Blase, Mona Ibrahim, Sally Elsamanoudi, Stephen A. Brassell, Bungo Furusato, Norbert Stingle, Isabell A. S...> ;Clinical Cancer Research. 2010 Mar 1
• 30 citations
  Prostate Cancer Risk Allele Specific for African Descent Associates with Pathologic Stage at Prostatectomy
  Eric J. Whitman, Mark Pomerantz, Yongmei Chen, Michael M. Chamberlin, Bungo Furusato, Chunling Gao, Amina Ali, Lakshmi Ravindranath, Albert Dobi, Isabell A. Sestrehenn...> ;Cancer Epidemiology, Biomarkers & Prevention. 2010 Jan 1
• 124 citations
  PCA3 score before radical prostatectomy predicts extracapsular extension and tumor volume.
  Eric J. Whitman, Jack Groskopf, Amina Ali, Yongmei Chen, Amy Blase, Bungo Furusato, Gyorgy Petrovics, Mona Ibrahim, Sally Elsamanoudi, Jennifer Cullen, Isabell A. Sest...> ;The Journal of Urology. 2008 Nov 1
• 194 citations
  TMPRSS2-ERG fusion, a common genomic alteration in prostate cancer activates C-MYC and abrogates prostate epithelial differentiation.
  Chen Sun, Albert Dobi, Ahmed A. Mohamed, Hongzhen Li, Rajesh L. Thangapazham, Bungo Furusato, Syed Shaheduzzaman, Shyh-Han Tan, Ganesan Vaidyanathan, Eric J. Whitman, ...> ;Oncogene. 2008 Sep 11
• 5 citations
  Merkel cell carcinoma as a solitary metastasis to the testis.
  Eric J. Whitman, Stephen A. Brassell, Inger L. Rosner, Joel T. Moncur> ;Journal of Clinical Oncology. 2007 Aug 20
• Autologous tumor-derived HSPPC-96 vs. physician's choice (PC) in a randomized phase III trial in stage IV melanoma.
  Richards J, Testori A, Whitman E, Mann GB, Lutzky J, Camacho L, Parmiani G, Hoos A, Gupta R, Srivastava P> ;J. Clin. Oncol.. 2006-06-20
• High-dose Allovectin-7 in patients with advanced metastatic melanoma: final phase 2 data and design of phase 3 registration trial.
  Richards JM, Bedikian A, Gonzalez R, Atkins MB, Whitman E, Lutzky J, Morse MA, Amatruda T, Galanis E, Thompson J> ;J. Clin. Oncol.. 2005-06-01
• 14 citations
  Pharmacokinetics of histamine dihydrochloride in healthy volunteers and cancer patients: implications for combined immunotherapy with interleukin-2.
  Mark R. Middleton, Mark Sarno, Sanjiv S. Agarwala, John A. Glaspy, Aziz Laurent, Kelly M. McMasters, Peter Naredi, Steven J. O'Day, Eric Whitman, Sarah Danson, Rebecca...> ;Journal of Clinical Pharmacology. 2002 Jul 1
• A phase 2 study of high-dose Allovectin-7 in patients with advanced metastatic melanoma.
  Bedikian, A. Y., Richards, J., Kharkevitch, D., Atkins, M. B., Whitman, E., Gonzalez, R.> ;Melanoma Res. 2010 Jun
• A multi-center phase II evaluation of the small molecule survivin suppressor YM155 in patients with unresectable stage III or IV melanoma.
  Lewis, K. D., Samlowski, W., Ward, J., Catlett, J., Cranmer, L., Kirkwood, J., Lawson, D., Whitman, E., Gonzalez, R.> ;Invest New Drugs. 2011 Feb 01
• Phase II clinical trial of a granulocyte-macrophage colony-stimulating factor-encoding, second-generation oncolytic herpesvirus in patients with unresectable metastati...
  Senzer, N. N., Kaufman, H. L., Amatruda, T., Nemunaitis, M., Reid, T., Daniels, G., Gonzalez, R., Glaspy, J., Whitman, E., Harrington, K., Goldsweig, H., Marshall, T.,...> ;J Clin Oncol. 2009 Dec 01
• Randomized trial of an allogeneic melanoma lysate vaccine with low-dose interferon Alfa-2b compared with high-dose interferon Alfa-2b for Resected stage III cutaneous ...
  Mitchell, M. S., Abrams, J., Thompson, J. A., Kashani-Sabet, M., DeConti, R. C., Hwu, W. J., Atkins, M. B., Whitman, E., Ernstoff, M. S., Haluska, F. G., Jakowatz, J. ...> ;J Clin Oncol. 2007 May 20
• Results from a randomized phase III study comparing combined treatment with histamine dihydrochloride plus interleukin-2 versus interleukin-2 alone in patients with me...
  Agarwala, S. S., Glaspy, J., O'Day, S. J., Mitchell, M., Gutheil, J., Whitman, E., Gonzalez, R., Hersh, E., Feun, L., Belt, R., Meyskens, F., Hellstrand, K., Wood, D.,...> ;J Clin Oncol. 2002 Jan 1
• Phase III comparison of vitespen, an autologous tumor-derived heat shock protein gp96 peptide complex vaccine, with physician''s choice of treatment for stage IV melan...
  Testori, A., Richards, J., Whitman, E., Mann, G. B., Lutzky, J., Camacho, L., Parmiani, G., Tosti, G., Kirkwood, J. M., Hoos, A., Yuh, L., Gupta, R., Srivastava, P. K.> ;J Clin Oncol. 2008 Feb 20
• Join now to see all